when it comes to managing their type 1 diabetes, kids will be kids


Unique clinical burdens for your pediatric patients include:

  • a need for frequent monitoring and treatment adjustments because of glycemic variability, constant growth, and activity2

  • difficulty articulating symptoms2

  • cognitive dysfunction due to daily periods of hypo- and hyperglycemia3

  • trips to the emergency room due to severe hypo- and hyperglycemia4

     


 

with Dexcom, your pediatric patients can be free to be a kid

As the CGM with unparalleled flexibility, Dexcom G7 fits into pediatric patients' lives

for patients 2 years and older

first-and-only waterproof CGM*,5

30-minute warmup, 2x faster than any other CGM

first-and-only CGM with direct connectivity to Apple Watch

exceptional accuracy in the moments that matter most6

Dexcom defines the gold standard of accuracy5,7

8.1%

MARD in pediatrics
Dexcom G7


Using Dexcom CGM in young patients with

type 1 diabetes can lead to:

down arrow

reduced hypoglycemic events by

48%

up arrow

increased time in range by

11.1%

within 8 weeks

 

 

Image
test

a clear connection: Dexcom-powered AID leads to improved outcomes12-14

 

2 Real-world studies put Dexcom CGM to the test

Image
Dexcom G7 CGM
Image
Dexcom G7 CGM

caring for a child with type 1 diabetes can be overwhelming-
give your caregivers peace of mind with Dexcom G715

Dexcom CGM offers multiple features to help protect your pediatric patients:

check markUrgent Low Sooncheck mark12-hour grace period
check markDelay First High Alertcheck markRise rate
check markDexcom Follow‡‡check markFall rate
clarity iconWhen used to share glucose data with one or more followers, Dexcom Follow is associated with16:
down arrowlower mean glucoseup arrow more time spent in range
down arrowless time in hyper- and hypoglycemiaup arrow significantly higher CGM utilization

DEXCOM FOLLOW APP

Dexcom Follow App Screen

AID = automated insulin delivery; CGM = continuous glucose monitoring; CIQ = Control-IQ Technology; CLIO = Control-IQ Observational; DKA = diabetic ketoacidosis; MARD = mean absolute relative difference; TIR = time in range.  

*The Dexcom G7 Sensor is water-resistant and may be submerged under 8 feet of water for up to 24 hours without failure when properly installed. †Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ‡Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. §In very young children (aged 2-7 years). ||Results obtained with a previous generation Dexcom CGM system and are applicable to G6/G7 given similar feature sets and better performance and usability. ¶In adolescents (aged 16-24 years). #Adverse events were reported monthly over 12 months and were compared to historical data from the T1D Exchange. Patient-reported outcomes were assessed quarterly. All study visits were virtual. **N=9028 using the time-weighted average target of 110 mg/dL. ††Hypoglycemia consensus target of <4% time below 70 mg/dL. ‡‡Separate Follow app and internet connection required.

1 Dexcom, Data on File, 2025. 2 Streisand R, et al. Curr Diab Rep. 2014;14(9):520. 3 Gonder-Frederick LA, et al. Diabetes Care. 2009;32(6):1001-1006. 4 Mulinacci G, et al. Diabetes Technol Ther. 2019;21(1):6-10. 5 Dexcom G7 User Guide, 2023. 6 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. 7 FreeStyle Libre 3 User Guide. 8 DiMeglio LA, et al. Diabetes Care. 2021;44(2):464-472. 9 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 10 Thabit H, et al. Diabetes Care. 2020;43(10):2537-2543. 11 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf. 12 Graham R, et al. Diabetes Technol Ther. 2024;26(1):24-32. 13 Breton MD, et al. Diabetes Technol Ther. 2021;23(9):601-608. 14 Forlenza GP, et al. Diabetes Technol Ther. 2024;26(8):514-525. 15 Polonsky WH, et al. J Diabetes Sci Technol. 2022;16(1):97-105. 16 Welsh JB, et al. Diabetes Ther. 2019;10(2):751-755.

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

Contact Reason

Please note: To ensure a successful transaction, please provide information that matches the Provider’s medical license information. A valid business address is required for a request to be fulfilled.

Do not include prefix (Mr., Mrs., Dr.)
As listed on Provider’s medical license (no MD, Jr., Sr.)
Please use the Provider’s NPI
Please provide Facility/Office address Only- We will not ship to home address
Is your patient on a connected pump device?

 

By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.